This is an 18-month, randomized, double-blind study enrolling approximately 1,566 participants across 200 sites worldwide. The participants for this study must be between the ages 50-90 and have a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's disease (AD). After the completion of the main 18 month study phase and if you meet the eligibility criteria, you will receive an invitation to participate in an optional open-label extension study phase.
What is the purpose of the BAN2401 study?
The purpose of this study is to test the safety and effectiveness of an investigational drug, BAN2401, in treating participants who have mild cognitive impairment (MCI) or mild Alzheimer's disease (AD). Participants in the study will be randomly assigned to receive either the investigational drug or placebo, which is an inactive substance designed to look like a medication, but has no effect. Both the investigational drug and placebo will be administered intravenously every 2 weeks.
Men and women between the ages of 50 – 90 who have a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). All participants must have a study partner who spends at least 8 hours per week with them and would be able to support them throughout the duration of the study. There is a screening phase during which you will answer several questionnaires to help determine whether you are eligible.
If you are interested in learning more about theBAN2401study, please call (401) 455-6402 or send an e-mail firstname.lastname@example.org. Ask about the “BAN2401 Study.”